Equillium, Inc.

EQ

US29446K1060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
1.54 ^USD	+0.65%		-10.47%	+113.00%

May. 09	Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M	MT
May. 09	Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Equillium, Inc. Announces Cessation of Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer

February 16, 2022 at 07:01 am EST

On February 11, 2022, it was determined that Dolca Thomas, M.D. would cease serving as the Company's Executive Vice President of Research & Development and Chief Medical Officer and separate from the Company effective as of February 25, 2022.

Latest news about Equillium, Inc.

Earnings Flash (EQ) EQUILLIUM Reports Q1 Revenue $10.7M	May. 09	MT
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
H.C. Wainwright Adjusts Price Target on Equillium to $5 From $4, Keeps Buy Rating	Apr. 02	MT
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis	Apr. 01	CI
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	Mar. 26	DJ
Equillium Swings to Q4 Loss As Revenue Falls	Mar. 25	MT
Equillium, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Equillium, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 25	CI
Earnings Flash (EQ) EQUILLIUM Reports Q4 Revenue $9.2M	Mar. 25	MT
HC Wainwright Adjusts Price Target on Equillium to $4 From $4.50, Keeps Buy Rating	Dec. 26	MT
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 21	CI
HC Wainwright Adjusts Equillium's Price Target to $4.50 From $5.50, Maintains Buy Rating	Nov. 13	MT
Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology	Nov. 13	CI
Tranche Update on Equillium, Inc. (NasdaqCM:EQ)'s Equity Buyback Plan announced on August 2, 2023.	Nov. 08	CI
Equillium, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (EQ) EQUILLIUM Reports Q3 Revenue $8.9M	Nov. 08	MT
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology	Nov. 06	CI
Transcript : Equillium, Inc. - Analyst/Investor Day	23-10-16
Equillium, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (EQ) EQUILLIUM Posts Q2 Revenue $9.1M	23-08-09	MT
Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer	23-08-09	CI
Equillium Board Approves $7.5 Million Share Buyback Program	23-08-03	MT
Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.	23-08-02	CI
Equillium, Inc. authorizes a Buyback Plan.	23-08-01	CI
Equillium, Inc.(NasdaqGM:EQ) dropped from Russell 3000E Growth Index	23-06-23	CI

Chart Equillium, Inc.

Duration

Period

More charts

Company Profile

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Companyâs pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Companyâs EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.

Sector

Pharmaceuticals

Calendar

2024-05-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Equillium, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.54 USD

Average target price

6.75 USD

Spread / Average Target

+338.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EQUILLIUM, INC.	+113.00%	54.29M
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+32.39%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.50%	240B
NOVARTIS AG	+9.56%	209B
ROCHE HOLDING AG	-9.04%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals

Equillium, Inc.

Equities

EQ

US29446K1060

Pharmaceuticals

Equillium, Inc. Announces Cessation of Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer

EPS Revisions